全文获取类型
收费全文 | 3919篇 |
免费 | 180篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 96篇 |
妇产科学 | 41篇 |
基础医学 | 562篇 |
口腔科学 | 108篇 |
临床医学 | 175篇 |
内科学 | 780篇 |
皮肤病学 | 46篇 |
神经病学 | 314篇 |
特种医学 | 106篇 |
外科学 | 816篇 |
综合类 | 23篇 |
预防医学 | 93篇 |
眼科学 | 44篇 |
药学 | 306篇 |
中国医学 | 8篇 |
肿瘤学 | 584篇 |
出版年
2023年 | 14篇 |
2022年 | 20篇 |
2021年 | 69篇 |
2020年 | 50篇 |
2019年 | 59篇 |
2018年 | 84篇 |
2017年 | 51篇 |
2016年 | 58篇 |
2015年 | 77篇 |
2014年 | 98篇 |
2013年 | 112篇 |
2012年 | 218篇 |
2011年 | 230篇 |
2010年 | 127篇 |
2009年 | 147篇 |
2008年 | 179篇 |
2007年 | 224篇 |
2006年 | 224篇 |
2005年 | 236篇 |
2004年 | 211篇 |
2003年 | 185篇 |
2002年 | 190篇 |
2001年 | 114篇 |
2000年 | 96篇 |
1999年 | 117篇 |
1998年 | 54篇 |
1997年 | 45篇 |
1996年 | 28篇 |
1995年 | 26篇 |
1994年 | 30篇 |
1993年 | 29篇 |
1992年 | 65篇 |
1991年 | 77篇 |
1990年 | 65篇 |
1989年 | 82篇 |
1988年 | 72篇 |
1987年 | 45篇 |
1986年 | 41篇 |
1985年 | 40篇 |
1984年 | 29篇 |
1983年 | 26篇 |
1982年 | 17篇 |
1981年 | 8篇 |
1980年 | 18篇 |
1979年 | 28篇 |
1978年 | 17篇 |
1977年 | 15篇 |
1974年 | 9篇 |
1972年 | 11篇 |
1971年 | 8篇 |
排序方式: 共有4120条查询结果,搜索用时 31 毫秒
1.
Takeshi Nagashima Ken Yamaguchi Kenichi Urakami Yuji Shimoda Sumiko Ohnami Keiichi Ohshima Tomoe Tanabe Akane Naruoka Fukumi Kamada Masakuni Serizawa Keiichi Hatakeyama Kenya Matsumura Shumpei Ohnami Koji Maruyama Tohru Mochizuki Masatoshi Kusuhara Akio Shiomi Yasuhisa Ohde Masanori Terashima Katsuhiko Uesaka Tetsuro Onitsuka Seiichiro Nishimura Yasuyuki Hirashima Nakamasa Hayashi Yoshio Kiyohara Yasuhiro Tsubosa Hirohisa Katagiri Masashi Niwakawa Kaoru Takahashi Hiroya Kashiwagi Masahiro Nakagawa Yuji Ishida Takashi Sugino Mitsuru Takahashi Yasuto Akiyama 《Cancer science》2020,111(2):687-699
This study aimed to establish the Japanese Cancer Genome Atlas (JCGA) using data from fresh frozen tumor tissues obtained from 5143 Japanese cancer patients, including those with colorectal cancer (31.6%), lung cancer (16.5%), gastric cancer (10.8%) and other cancers (41.1%). The results are part of a single‐center study called “High‐tech Omics‐based Patient Evaluation” or “Project HOPE” conducted at the Shizuoka Cancer Center, Japan. All DNA samples and most RNA samples were analyzed using whole‐exome sequencing, cancer gene panel sequencing, fusion gene panel sequencing and microarray gene expression profiling, and the results were annotated using an analysis pipeline termed “Shizuoka Multi‐omics Analysis Protocol” developed in‐house. Somatic driver alterations were identified in 72.2% of samples in 362 genes (average, 2.3 driver events per sample). Actionable information on drugs that is applicable in the current clinical setting was associated with 11.3% of samples. When including those drugs that are used for investigative purposes, actionable information was assigned to 55.0% of samples. Germline analysis revealed pathogenic mutations in hereditary cancer genes in 9.2% of samples, among which 12.2% were confirmed as pathogenic mutations by confirmatory test. Pathogenic mutations associated with non–cancerous hereditary diseases were detected in 0.4% of samples. Tumor mutation burden (TMB) analysis revealed 5.4% of samples as having the hypermutator phenotype (TMB ≥ 20). Clonal hematopoiesis was observed in 8.4% of samples. Thus, the JCGA dataset and the analytical procedures constitute a fundamental resource for genomic medicine for Japanese cancer patients. 相似文献
2.
3.
Shota Nukaga Takuya Mori Yoshihiro Miyagawa Rina FujiwaraTani Takamitsu Sasaki Kiyomu Fujii Shiori Mori Kei Goto Shingo Kishi Chie Nakashima Hitoshi Ohmori Isao Kawahara Yi Luo Hiroki Kuniyasu 《Cancer science》2020,111(12):4605
Cancer‐derived myocardial damage is an important cause of death in cancer patients. However, the development of dietary interventions for treating such damage has not been advanced. Here, we investigated the effect of dietary intervention with lauric acid (LAA) and glucose, which was effective against skeletal muscle sarcopenia in a mouse cachexia model, on myocardial damage. Treatment of H9c2 rat cardiomyoblasts with lauric acid promoted mitochondrial respiration and increased ATP production by Seahorse flux analysis, but did not increase oxidative stress. Glycolysis was also promoted by LAA. In contrast, mitochondrial respiration and ATP production were suppressed, and oxidative stress was increased in an in vitro cachexia model in which cardiomyoblasts were treated with mouse cachexia ascites. Ascites‐treated H9c2 cells with concurrent treatment with LAA and high glucose showed that mitochondrial respiration and glycolysis were promoted more than that of the control, and ATP was restored to the level of the control. Oxidative stress was also reduced by the combined treatment. In the mouse cachexia model, myocardiac atrophy and decreased levels of a marker of muscle maturity, SDS‐soluble MYL1, were observed. When LAA in CE‐2 diet was orally administered alone, no significant rescue was observed in the cancer‐derived myocardial disorder. In contrast, combined oral administration of LAA and glucose recovered myocardial atrophy and MYL1 to levels observed in the control without increase in the cancer weight. Therefore, it is suggested that dietary intervention using a combination of LAA and glucose for cancer cachexia might improve cancer‐derived myocardial damage. 相似文献
4.
Katsunobu Oyama Sachio Fushida Tomoya Tsukada Jun Kinoshita Toshifumi Watanabe Masatoshi Shoji Shinichi Nakanuma Koichi Okamoto Seisho Sakai Isamu Makino Keishi Nakamura Hironori Hayashi Masafumi Inokuchi Hisatoshi Nakagawara Tomoharu Miyashita Hidehiro Tajima Hiroyuki Takamura Itasu Ninomiya Hirohisa Kitagawa Takashi Fujimura Ryousuke Tajiri Akishi Ooi Tetsuo Ohta 《Journal of gastroenterology》2015,50(1):121-122
5.
6.
Yasushi Sawayama Hidehiro Itonaga Takuya Fukushima Nobuaki Nakano Hiroshi Fujiwara Atae Utsunomiya Takahiro Fukuda Toshihiro Miyamoto Tetsuya Eto Kaname Miyashita Hirohisa Nakamae Masao Ogata Atsushi Yamanoha Yasuhiko Miyazaki Junya Kanda Yoshiko Atsuta Koji Kato ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation 《American journal of hematology》2019,94(5):E143-E146
7.
8.
Yasushi Yamasaki Keita Harada Shumpei Yamamoto Eriko Yasutomi Shotaro Okanoue Mami Hirai Shohei Oka Yuka Obayashi Hiroyuki Sakae Kenta Hamada Toshihiro Inokuchi Hideaki Kinugasa Yuusaku Sugihara Masahiro Takahara Takehiro Tanaka Sakiko Hiraoka Yoshiro Kawahara Hiroyuki Okada 《Digestive endoscopy》2020,32(5):791-800
9.
Yujiro Nagata Takashi Kawahara Takuro Goto Satoshi Inoue Yuki Teramoto Guiyang Jiang Naohiro Fujimoto Hiroshi Miyamoto 《American journal of cancer research》2020,10(12):4386
We recently demonstrated that silodosin, a selective α1-blocker often prescribed for the symptomatic treatment of benign prostatic hyperplasia (BPH), could inactivate a c-fos proto-oncogene regulator ELK1 in bladder cancer cells possessing a functional androgen receptor (AR). However, the clinical impact of α1-blockers on the development and progression of bladder cancer remained poorly understood. In the present study, we investigated if α1-blockers clinically used, including silodosin, tamsulosin, and naftopidil, could prevent the neoplastic/malignant transformation and cell growth, using non-neoplastic urothelial SVHUC sublines with carcinogen/MCA challenge and bladder cancer lines, respectively. Bladder cancers in men treated with silodosin, tamsulosin, or naftopidil for their BPH were then compared. Silodosin at 1-10 µM significantly inhibited the neoplastic transformation of MCA-SVHUC-AR cells, but not that of AR-negative MCA-SVHUC-control cells. In MCA-SVHUC-AR, silodosin significantly reduced the expression levels of oncogenes (c-fos/NF-κB1) and induced those of tumor suppressors (p27/PTEN). However, tamsulosin (up to 1 µM) or naftopidil (up to 10 µM) failed to significantly inhibit the neoplastic transformation of AR-positive or AR-negative urothelial cells. Similarly, cell proliferation/migration of AR-positive bladder cancer lines was considerably inhibited only by silodosin. Meanwhile, the incidence of bladder cancer in patients with silodosin [49/540 (9.1%)] was marginally lower, compared to those with tamsulosin [64/523 (12.2%); P=0.094] or tamsulosin or naftopidil [64+28/523+236 (12.1%); P=0.082]. There were no significant differences in tumor grade/stage among the 3 cohorts. Outcome analysis revealed lower risks for disease progression of non-muscle-invasive bladder tumors in the silodosin group than in the naftopidil group (P=0.011) or tamsulosin+naftopidil groups (P=0.035). Similarly, silodosin patients with muscle-invasive tumor had lower risks for disease progression, compared with tamsulosin (P=0.006) or tamsulosin+naftopidil (P=0.028) patients. Multivariate analysis further showed that silodosin treatment in those with non-muscle-invasive tumor was associated with improved progression-free survival, compared with naftopidil (hazard ratio=0.086; 95% confidence interval=0.008-0.905; P=0.041) or tamsulosin/naftopidil (hazard ratio=0.128; 95% confidence interval=0.016-1.036; P=0.054) treatment. Our in vitro studies thus indicate that both urothelial tumorigenesis and tumor growth are inhibited by silodosin, but not by tamsulosin or naftopidil. Clinical data further suggest that even pharmacological doses (e.g. 0.1 µM) of silodosin contribute to preventing bladder cancer progression. 相似文献